Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 07, 2024 04:09 ET | Source: Research and Markets

Pancreatic Cancer Drugs Global Market Report 2024

Dublin, March 07, 2024 (GLOBE NEWSWIRE) -- The "Pancreatic Cancer Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The pancreatic cancer drugs market size...
December 11, 2023 11:58 ET | Source: Research and Markets

Lung Cancer Drugs Global Market Report 2024 - Regulatory Approvals and Increased Patient Awareness and Education Propel the Market

Dublin, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The "Lung Cancer Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The lung cancer drugs market size has grown...
December 21, 2021 04:33 ET | Source: Research and Markets

Global Lung Cancer Drugs Market (2021 to 2030) - Featuring Bristol-Myers Squibb, Merck & Co and F. Hoffmann-La Roche Among Others

Dublin, Dec. 21, 2021 (GLOBE NEWSWIRE) -- The "Lung Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering. This...
October 14, 2014 09:00 ET | Source: Nuvilex, Inc.

Nuvilex's Cancer Treatment Obtaining FDA Orphan Drug Status Would Make Company Attractive Big Pharma Target

NEW YORK, NY--(Marketwired - October 14, 2014) - Nuvilex, Inc. (OTCQB: NVLX) has officially introduced its advanced pancreatic cancer treatment to the U.S. Food and Drug Administration (FDA) in an...
February 19, 2014 09:00 ET | Source: Nuvilex, Inc.

Nuvilex's Pancreatic Cancer Treatment Readies to Challenge Eli Lilly and Celgene in Late-Phase Clinical Trials

NEW YORK, NY--(Marketwired - Feb 19, 2014) - Nuvilex, Inc. (OTCQB: NVLX) is a small biotech firm in Silver Spring, Maryland, that hopes to soon be mentioned with much larger biotechnology and...
December 16, 2013 09:15 ET | Source: Nuvilex, Inc.

Nuvilex to Answer Increasing Calls for Better Pancreatic Cancer Treatment Without Gemcitabine

NEW YORK, NY--(Marketwired - Dec 16, 2013) - Nuvilex, Inc. (OTCQB: NVLX) may be just what the National Cancer Institute (NCI) and a growing number of doctors ordered - the company's late stage...
September 09, 2013 08:30 ET | Source: Nuvilex, Inc.

FDA Approves ABRAXANE(R) for Pancreatic Cancer, Could Nuvilex's Treatment Be Next

NEW YORK, NY--(Marketwired - Sep 9, 2013) - After presenting the results of its large scale Phase III clinical trial at the 2013 Gastrointestinal Cancers Symposium of the American Society of...
August 15, 2013 08:30 ET | Source: Nuvilex, Inc.

Stock Market Media Group Issues Nuvilex, Inc. Road to Phase III Clinical Trials Report

NEW YORK, NY--(Marketwired - Aug 15, 2013) - Stock Market Media Group, a research and content development investor relations firm, issued its Third Quarter Update and the first installment of its...
July 18, 2013 08:30 ET | Source: Nuvilex, Inc.

Nuvilex, Inc. Acquisition Could Be Steal of the Century and Worth Billions

NEW YORK, NY--(Marketwired - Jul 18, 2013) - In a recently announced acquisition deal, Nuvilex, Inc. (OTCQB: NVLX), pulled off what can only be described as the steal of the century. The company...